Home›Companies›Biotech & Pharma›Allotera

Allotera Therapeutics, Inc.

Develops donor-cell therapies for people with blood cancers.

Updated Nov 10, 2026·Latest SEC filing Jul 23, 2026·Suggest an edit

About Allotera

Allotera is a private company based in St. Louis, Missouri. It has reported $259,047,194 raised in three offerings on Form D since July 2021. Its chief executive is Kumar Srinivasan.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Aug 22, 2025Sep 8, 2025amended Jul 23, 2026$123,313,778of $163.0M target20$6.1MEquity, Options, Securities on exerciseRule 506(b)Form D/A ↗1 earlier filing
Jul 9, 2021Jul 23, 2021$98,500,011of $172.0M target27$3.6MEquityRule 506(b)Form D ↗
Apr 13, 2020Jul 23, 2021$37,233,405fully sold6$6.2MEquityRule 506(b)Form D ↗
Total, three offerings$259,047,194

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Allotera's Form D filed Jul 23, 2026.

DD
Drew Dennison
Director
Also a director at AI Proteins and SimpleRose.
KL
Kevin Li
Director
Kumar Srinivasan
Kumar Srinivasan
President & Chief Executive Officer, director
Also a director at Pulmotect.
Matthew Cooper
Matthew Cooper
Co-Founder & Chief Scientific Officer
Cherry Thomas
Cherry Thomas
Chief Medical Officer
Ayman Kabakibi
Ayman Kabakibi
Chief Operating Officer & EVP, R&D
BM

Earlier filings also listed John McKearn (director, last listed Jul 2021), Jan Davidson (executive officer, last listed Jul 2021) and Daniel Kemp (president and chief executive officer, director, last listed Jul 2021).

Sources

  1. SECAllotera Therapeutics, Inc. Form D, filed Sep 8, 2025
  2. SECAllotera Therapeutics, Inc. filing history
  3. CompanyPrivacy notice
  4. CompanyCompany overview
  5. CompanyLeadership
  6. CompanyBoard of directors